NCT06425042 Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity
| NCT ID | NCT06425042 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Finis Terrae University |
| Condition | Healthy Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 28 participants in total. It began in 2024-03-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.
Eligibility Criteria
Inclusion Criteria: * Participants are able to provide signed and dated written informed consent prior to any study specific procedures * Aged ≥ 60 and ≤ 80 years * Body mass index (BMI) 25 - 35 kg/m2 * Stable dietary habits (no weight loss or gain \> 5 kg in the past 3 months) * No signs of active cardiovascular disease, liver or kidney malfunction Exclusion Criteria: * Patients with congestive heart failure and and/or severe renal and or liver insufficiency * Uncontrolled hypertension * Any contra-indication for MRI scanning * Alcohol consumption of \> 3 servings per day for man and \>2 servings per day for woman * Smoking * Unstable body weight (weight gain or loss \> 5kg in the last 3 months) * Engagement in structured exercise activities \> 2 hours a week * Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator which would possibly hamper our study results * Use of food supplements containing NR or Resveratrol (similar working mechanisms)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06425042 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Healthy Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06425042 currently recruiting?
Yes, NCT06425042 is actively recruiting participants. Contact the research team at rmancilla@uft.cl for enrollment information.
Where is the NCT06425042 trial being conducted?
This trial is being conducted at Santiago, Chile.
Who is sponsoring the NCT06425042 clinical trial?
NCT06425042 is sponsored by Finis Terrae University. The trial plans to enroll 28 participants.